Merck Scores Latest Label Expansion for Keytruda in Esophageal Carcinomas

Merck’s blockbuster Keytruda (pembrolizumab) won another regulatory victory, making it the first checkpoint inhibitor approved by the U.S. Food and Drug Administration (FDA) for first-line treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction carcinomas regardless of PD-L1 expression.